drugset / Trial / NCT06796803
Camrelizumab Combined With Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC)
Phase 2/3
Recruiting
398 enrolled
Shanghai Zhongshan Hospital
Jiangsu Hengrui Pharmaceutical Co., Ltd. · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this phase 2/3 study is to investigate the efficacy and safety of camrelizumab combined with rivoceranib and hepatic arterial infusion chemotherapy (HAIC) as conversion therapy for Potentially Resectable HCC.
Timeline
- Start
- 2025-02-20
- Primary completion
- 2028-02-20
- Completion
- 2030-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Camrelizumab | Monoclonal antibody | — | — |
| Background | Rivoceranib | Small molecule | — | — |